Navigation Links
Anastrozole Confirmed Superior in Breast Cancer Prevention

SAN ANTONIO, Dec. 14 /PRNewswire/ -- Anastrozole is more effective than tamoxifen at preventing breast cancer recurrence for periods of at least 10 years in women with hormone-responsive cancers. In addition, the increased risk of fractures that has been seen in some patients being treated with anastrozole disappears after treatment ends.

Speaking at the Thursday session of the San Antonio Breast Cancer Symposium, Professor John Forbes of the University of Newcastle presented the much-anticipated long-term results of the ATAC (Anastrozole, Tamoxifen, Alone or in Combination) trial that compared 5 years of tamoxifen with 5 years of the aromatase inhibitor anastrozole for the treatment of postmenopausal women with invasive breast cancer.

Hormone-responsive breast cancers require estrogen stimulation in order to grow. Tamoxifen, a synthetic variation of estrogen, binds to hormone receptors on hormone-sensitive cancer cells, preventing estrogen from attaching to the cells. Anastrozole, on the other hand, prevents the manufacture of estrogen by body tissues other than the ovaries (e.g., fat cells), so it is useful for the treatment of hormone-sensitive cancers in postmenopausal women whose ovaries are no longer producing estrogen.

Although previous reports at 33 and 68 months demonstrated that anastrozole was more effective, has fewer serious side effects, and was better tolerated than tamoxifen during the period of treatment, it was not known whether the benefits or side effects associated with anastrozole would persist long term after patients were no longer taking the drug.

After 10 years (5 years after the completion of treatment), patients who had taken anastrozole continued to show reduced rates of tumor recurrence and metastasis compared with patients who had taken tamoxifen. In fact, the relative benefit of anastrozole actually increased compared with results seen immediately after the completion of treatment.

Most strikingly, the incidence of a new cancer occurring in the other breast was significantly lower at 10 years in women who took anastrozole compared with those who received tamoxifen. Tamoxifen has been approved for several years for use in preventing new breast cancers, and it now appears that anastrozole may be even more effective.

Many patients have been reluctant to begin treatment with anastrozole because of concern about the potential for increased bone loss and risk of fracture that can occur with the use of aromatase inhibitors. It was not known whether these effects would persist after the end of treatment. With the new data presented today, it appears that they do not. Although the incidence of fractures was nearly 30% higher in patients treated with anastrozole while they were taking the drug, that difference disappeared after treatment was completed. In addition, there do not appear to be any other important side effects related to anastrozole treatment at this time.

SOURCE San Antonio Breast Cancer Symposium
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Game Commission Announces EHD Confirmed in Fayette County
2. Oritavancin Demonstrates Superior In Vitro Activity to Vancomycin and Metronidazole Against C. Difficile Bacteria
3. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
4. Edwards Resilient Trial Demonstrates Statistically Superior Results for Treating Peripheral Arterial Disease in the Leg
5. IDM Pharma Announces Updated Phase 3 Mifamurtide (L-MTP-PE) Data Confirms Statistically Superior Overall Survival in Osteosarcoma Patients
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
8. Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
9. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
10. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
11. Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer
Post Your Comments:
(Date:11/24/2015)... 24, 2015 F1000Workspace - a ... since it was launched just six months ago. --> ... authoring platform for scientists - since it was launched just ... been loaded on to F1000Workspace - a research ... it was launched just six months ago. ...
(Date:11/24/2015)... st  Scientific Assembly and Annual Meeting of the Radiological ... in Chicago on Nov-29 th through ... st  Scientific Assembly and Annual Meeting of the Radiological Society of ... Chicago on Nov-29 th through Dec-4 th ... will present its revolutionary whole body CZT digital SPECT/CT solution at ...
(Date:11/24/2015)... , Nov. 24, 2015 Teledyne DALSA , ... image sensing technology, will introduce its CMOS X-Ray detector ... , November 29 to December 3, at McCormick Place in ... detectors for diagnostic and interventional imaging will be on display ... family of advanced CMOS X-Ray detectors is the industry ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... ... Dr. Todd S. Afferica, a noted general dentist in Norcross, GA ... Afferica now uses the BIOLASE WaterLase iPlus 2.0™ in many of his dental procedures. ... traditional cutting tools, such as the scalpel and high-speed drill, which can both cause ...
(Date:11/24/2015)... ... November 24, 2015 , ... In an article published November ... determine which patients are or are not eligible for bariatric surgery. The article explains ... 40, are more than 100 pounds overweight, or have a BMI of 35 and ...
(Date:11/24/2015)... ... November 24, 2015 , ... It takes only three to five ... is critical that the first impression be positive and reflects business values. If a ... buy anything or want to return. They will also share their thoughts about a ...
(Date:11/24/2015)... ... 24, 2015 , ... Cancer patients, survivors, caregivers, family members ... live taping of the next CURE Connections® video series on Saturday, ... Symposium at Georgetown University Hotel & Conference Center in Washington, D.C. , CURE ...
(Date:11/24/2015)... ... November 24, 2015 , ... Aided by seed funding from the ... study designed to yield insights into how to detect and treat pancreatic cancer (PC). ... cancer from small, non-coding RNA molecules (ncRNA), genetic material that is present in the ...
Breaking Medicine News(10 mins):